Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT0596 in Plasma Cell Leukemia
NCT06988059Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT0596 in plasma cell leukemia (PCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Adverse Events (AE) after CT0596 infusion at 12 months and Maximum Tolerated Dose and/or dose range at 12 months. Started Jun 2025; status: recruiting.
02
Drugs
CT0596
03
Conditions
plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT06988059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06988059.